MARKET OUTLOOK
Giant cell arteritis (GCA) is an autoimmune disease marked by inflammation of blood vessels in the head and neck, leading to persistent headaches, flu-like symptoms, and risk of blindness. The most common treatment for GCA is high doses of corticosteroids, typically started immediately after diagnosis to reduce the risk of blindness and tapered over the next 12-24 months. In 2017, the first targeted treatment for GCA, Roche’s Actemra, was approved. Other key autoimmune drugs, including Bristol Myers Squibb’s Orencia, AbbVie’s Rinvoq, and Sobi’s Kineret, are in late-phase trials for GCA, suggesting increasing interest in this potentially lucrative and untapped market.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key companies: Bayer, Genentech / Roche, Novartis, Janssen, Bristol Myers Squibb
Key drugs: Actemra, Stelara, Cosentyx, Orencia, corticosteroids, methotrexate, aspirin, hydroxychloroquine, dapsone